128 related articles for article (PubMed ID: 36890790)
1. Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy.
Kitamura W; Asada N; Naoi Y; Abe M; Fujiwara H; Ennishi D; Nishimori H; Fujii K; Fujii N; Matsuoka KI; Yoshino T; Maeda Y
Br J Haematol; 2023 Jul; 202(2):294-307. PubMed ID: 36890790
[TBL] [Abstract][Full Text] [Related]
2. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity.
Zanetti SR; Romecin PA; Vinyoles M; Juan M; Fuster JL; Cámos M; Querol S; Delgado M; Menendez P
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868394
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
5. What drives CAR-T emergent cytopenia?
Hills RK
Br J Haematol; 2023 Jul; 202(2):213-214. PubMed ID: 37009828
[TBL] [Abstract][Full Text] [Related]
6. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
7. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
[TBL] [Abstract][Full Text] [Related]
8. Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor-T cell therapy.
Yeung CCS; Woolston DW; Wu V; Voutsinas JM; Basom R; Davis C; Hirayama AV; Naresh KN
Eur J Haematol; 2024 Jan; 112(1):111-121. PubMed ID: 37526606
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
Salaroli A; Spilleboudt C; Bron D; Lewalle P
Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
[TBL] [Abstract][Full Text] [Related]
10. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
[TBL] [Abstract][Full Text] [Related]
11. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
Munshi PN; Ujjani C
Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Subtotal Lymphoid and Total Marrow Irradiation as Bridge Therapy to CD19-Directed CAR T Cells in a Chemorefractory DLBCL With Leukemic Involvement.
Saldi S; Perriello VM; Falini L; Ruggeri L; Fulcheri C; Ciardelli S; Innocente A; Ballanti S; Baffa N; Flenghi L; Pierini A; Aristei C; Falini B
Front Immunol; 2022; 13():934700. PubMed ID: 35911683
[TBL] [Abstract][Full Text] [Related]
13. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells.
Strati P; Li X; Deng Q; Marques-Piubelli ML; Henderson J; Watson G; Deaton L; Cain T; Yang H; Ravanmehr V; Fayad LE; Iyer SP; Nastoupil LJ; Hagemeister FB; Parra ER; Saini N; Takahashi K; Fowler NH; Westin JR; Steiner RE; Nair R; Flowers CR; Wang L; Ahmed S; Al-Atrash G; Vega F; Neelapu SS; Green MR
Cell Rep Med; 2023 Aug; 4(8):101158. PubMed ID: 37586321
[TBL] [Abstract][Full Text] [Related]
14. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy.
Chen PH; Lipschitz M; Weirather JL; Jacobson C; Armand P; Wright K; Hodi FS; Roberts ZJ; Sievers SA; Rossi J; Bot A; Go W; Rodig SJ
JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32484797
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
16. CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report.
Sun Z; Xie C; Liu H; Yuan X
Front Immunol; 2022; 13():778192. PubMed ID: 35154102
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
18. A potential role of preexisting inflammation in the development of acute myelopathy following CAR T-cell therapy for diffuse large B-cell lymphoma.
Beauvais D; Cozzani A; Blaise AS; Moreau AS; Varlet P; Gaggero S; Alidjinou EK; Vannod-Michel Q; Morschhauser F; Labalette M; Yakoub-Agha I; Mitra S
Curr Res Transl Med; 2022 May; 70(2):103331. PubMed ID: 34999480
[TBL] [Abstract][Full Text] [Related]
19. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Sauter CS; Senechal B; Rivière I; Ni A; Bernal Y; Wang X; Purdon T; Hall M; Singh AN; Szenes VZ; Yoo S; Dogan A; Wang Y; Moskowitz CH; Giralt S; Matasar MJ; Perales MA; Curran KJ; Park J; Sadelain M; Brentjens RJ
Blood; 2019 Aug; 134(7):626-635. PubMed ID: 31262783
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
